GO:0001883 purine nucleoside binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001883 purine nucleoside binding describes the molecular function of reversibly binding a purine nucleoside, a purine base linked to ribose or deoxyribose.
• The best-characterized proteins carrying this function are purine nucleoside phosphorylases (PNP), which bind purine nucleosides as substrates during phosphorolysis.
• PNP enzymes are trimeric or hexameric and show complex site cooperativity, including one-third-of-the-sites binding in transition states.
• Transition-state analogue and binding isotope effect studies have revealed the geometric and electronic features of purine nucleoside recognition.
• MTAP deletion, which causes accumulation of the purine nucleoside metabolite MTA, creates a dependency on PRMT5 and is a validated synthetic lethal target in cancer.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect purine nucleoside binding proteins in disease and drug discovery.
Description
GO:0001883 purine nucleoside binding is a molecular function term in the Gene Ontology that defines the selective, non-covalent interaction with a purine nucleoside, a compound consisting of a purine base linked either to ribose or deoxyribose. This function is central to nucleoside metabolism, nucleic acid salvage, and cellular signaling, and it is experimentally best understood in purine nucleoside phosphorylase (PNP) enzymes that catalyze the reversible phosphorolysis of purine nucleosides. Because purine nucleosides participate in DNA/RNA synthesis, energy metabolism, and methyl-transfer reactions, proteins that bind them are attractive targets for oncology, immunology, and antiviral research. Researchers study purine nucleoside binding to understand substrate recognition, catalytic mechanism, and allosteric regulation in enzymes such as PNP. Structural and kinetic work has shown that PNP binds purine nucleosides with high specificity and can exhibit negative cooperativity or half-of-the-sites reactivity depending on the oligomeric state. Transition-state analogue design and binding isotope effects have further defined the precise interactions that stabilize the purine nucleoside in the active site. In disease, dysregulated purine nucleoside binding and metabolism are linked to cancer, immunodeficiency, and parasite infections. MTAP-deleted tumors accumulate the purine nucleoside metabolite methylthioadenosine (MTA), which binds and inhibits PRMT5, creating a targetable vulnerability. This makes GO:0001883 a high-value term for functional genomics, drug discovery, and CRISPR-based model generation.
purine nucleoside binding At A Glance
| GO ID | GO:0001883 |
|---|---|
| GO term | purine nucleoside binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Reversible, non-covalent binding of purine nucleosides (purine base linked to ribose or deoxyribose) |
| Representative proteins | Purine nucleoside phosphorylases (PNP), nucleoside transporters, and purine salvage enzymes |
| Biological context | Nucleoside salvage, purine metabolism, methylthioadenosine (MTA) handling, and transition-state catalysis |
| Disease relevance | Cancer (MTAP deletion, PRMT5 dependency), immunodeficiency, and parasitic infections |
| Research methods | Crystallography, binding isotope effects, kinetic assays, CRISPR KO/point-mutation/knock-in models |
What Is GO:0001883?
In your own words, GO:0001883 purine nucleoside binding is the molecular function of selectively and reversibly binding a purine nucleoside, where a purine base (such as adenine or guanine) is linked to a ribose or deoxyribose sugar. This binding is non-covalent and is typically the first step in substrate recognition by enzymes and receptors that process purine nucleosides.
Why Is purine nucleoside binding Important in Cell Biology?
GO:0001883 purine nucleoside binding is important because it governs how cells recognize and process purine nucleosides, which are essential for nucleotide salvage, DNA/RNA synthesis, and methyl-transfer metabolism. Defects in purine nucleoside binding and metabolism cause immunodeficiency and are exploited by tumors with MTAP deletion, where MTA accumulation alters PRMT5 activity and creates a synthetic lethal dependency. Understanding this function at atomic and cellular resolution enables rational drug design, biomarker development, and CRISPR-based disease modeling.
• Purine nucleoside binding is the first step in purine salvage and nucleoside phosphorolysis, critical for nucleotide homeostasis.
• PNP enzymes that bind purine nucleosides are validated drug targets for T-cell malignancies and parasitic diseases.
• MTAP-deleted cancers accumulate MTA, a purine nucleoside metabolite, leading to PRMT5 inhibition and a targetable vulnerability.
• Transition-state analogue design relies on precise knowledge of purine nucleoside binding geometry.
• Binding isotope effects provide direct experimental evidence for transition-state interactions in PNP.
• Oligomeric PNP shows one-third-of-the-sites binding, a model for allosteric cooperativity in purine nucleoside recognition.
• Symmetric nucleoside inhibitors exploit purine nucleoside binding pockets for therapeutic development.
• CRISPR screens can identify genes whose loss alters sensitivity to purine nucleoside binding inhibitors.
• Purine nucleoside binding proteins are relevant to neurodegeneration and immune disorders through altered purine metabolism.
• Structural snapshots of ligand binding to hexameric PNP reveal dynamic active-site changes during catalysis.
Molecular Function of purine nucleoside binding
Substrate recognition and initial binding
In simple terms: The protein first grabs the purine nucleoside in a specific pocket.
Purine nucleoside binding begins with recognition of the purine base and sugar moieties within a defined active-site pocket. Crystallographic snapshots of hexameric purine nucleoside phosphorylase (PNP) show that ligand binding induces local conformational changes that position the nucleoside for catalysis. The enzyme discriminates purine nucleosides from pyrimidine nucleosides through hydrogen-bonding and stacking interactions with the purine ring.
Oligomeric assembly and site cooperativity
In simple terms: The protein often works as a multi-part machine, and binding at one site affects the others.
PNP enzymes are typically trimeric or hexameric, and purine nucleoside binding can exhibit cooperativity. Studies on trimeric PNP explored the postulated one-third-of-the-sites binding in the transition state, showing that not all subunits bind ligand simultaneously. This cooperativity modulates catalytic efficiency and is a key feature of the molecular function.
Transition-state interactions
In simple terms: The protein grips the nucleoside most tightly when it is in a strained, reactive shape.
Transition-state analogue studies and binding isotope effects have revealed the precise interactions that stabilize the purine nucleoside in the transition state. Tight-binding transition state analogues of PNP were designed based on the meaning, design, and properties of these interactions. Binding isotope effects provided direct evidence for transition-state interactions in PNP, confirming the geometric and electronic features of purine nucleoside binding.
Inhibition and chemical probes
In simple terms: Synthetic molecules can mimic the nucleoside and block the protein.
Symmetric nucleosides have been developed as potent purine nucleoside phosphorylase inhibitors, exploiting the binding pocket to compete with natural purine nucleosides. These inhibitors are valuable tools for probing the function of purine nucleoside binding in cells and for therapeutic development.
Kinetic mechanism and catalysis
In simple terms: Binding is followed by a chemical reaction that breaks the nucleoside apart.
Kinetic studies of hexameric PNP combined with crystallographic snapshots have provided insight into the catalytic mechanism following purine nucleoside binding, including the order of substrate addition and product release. The binding step is reversible and precedes phosphorolysis, linking the molecular function directly to purine salvage and metabolism.
Key Genes Involved in GO:0001883 purine nucleoside binding
The following genes and proteins are experimentally linked to purine nucleoside binding, either as direct binders, metabolic enzymes, or disease-relevant modifiers.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PNP | Purine nucleoside phosphorylase; binds purine nucleosides and catalyzes phosphorolysis | Central enzyme for GO:0001883; target for transition-state analogues and inhibitors |
| MTAP | Methylthioadenosine phosphorylase; binds MTA, a purine nucleoside | Deleted in many cancers; loss causes MTA accumulation and PRMT5 dependency |
| PRMT5 | Protein arginine methyltransferase; inhibited by MTA binding | Synthetic lethal target in MTAP-deleted tumors |
| ADA | Adenosine deaminase; binds adenosine, a purine nucleoside | Defects cause severe combined immunodeficiency; related to purine nucleoside metabolism |
| ADK | Adenosine kinase; binds adenosine for phosphorylation | Regulates adenosine levels and purine salvage |
| ENT1 (SLC29A1) | Equilibrative nucleoside transporter; binds and transports purine nucleosides | Determines cellular uptake of nucleoside drugs |
| ENT2 (SLC29A2) | Equilibrative nucleoside transporter; binds purine nucleosides | Modulates nucleoside analog sensitivity |
| CNT2 (SLC28A2) | Concentrative nucleoside transporter; binds purine nucleosides | Influences purine nucleoside availability |
| CNT3 (SLC28A3) | Concentrative nucleoside transporter; binds purine nucleosides | Broad specificity for purine nucleosides |
| DCK | Deoxycytidine kinase; binds deoxyadenosine and other nucleosides | Activates nucleoside analogs in cancer therapy |
| HPRT1 | Hypoxanthine phosphoribosyltransferase; salvages purine bases | Defects cause Lesch-Nyhan syndrome; linked to purine salvage |
| APRT | Adenine phosphoribosyltransferase; salvages adenine | Defects cause 2,8-dihydroxyadenine urolithiasis |
| XDH | Xanthine dehydrogenase; purine catabolism | Produces uric acid; relevant to gout and purine metabolism |
| GART | Phosphoribosylglycinamide formyltransferase; de novo purine synthesis | Balances de novo synthesis with salvage |
| ATIC | AICAR transformylase/IMP cyclohydrolase; de novo purine synthesis | Target in purine metabolism studies |
| PPAT | Phosphoribosyl pyrophosphate amidotransferase; de novo purine synthesis | Rate-limiting enzyme in purine synthesis |
| NUDT5 | Nudix hydrolase; binds and hydrolyzes purine nucleoside diphosphates | Modulates purine nucleotide pools |
| SAMHD1 | Binds deoxynucleoside triphosphates and regulates dNTP pools | Relevant to innate immunity and purine nucleoside metabolism |
How Is purine nucleoside binding Regulated?
Purine nucleoside binding is regulated at multiple levels. Enzyme expression levels of PNP and MTAP determine the capacity for purine nucleoside turnover. Allosteric cooperativity in oligomeric PNP modulates binding affinity and catalysis, as shown by one-third-of-the-sites binding models. Substrate availability, including MTA accumulation upon MTAP deletion, directly affects binding to downstream effectors such as PRMT5. Post-translational modifications and cellular localization of nucleoside transporters also influence the effective concentration of purine nucleosides available for binding.
purine nucleoside binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MTAP | Cancer; MTAP deletion leads to MTA accumulation and PRMT5 dependency | MTAP knockout cancer cell lines; isogenic pairs with and without MTAP |
| PRMT5 | Cancer; synthetic lethal target in MTAP-deleted tumors | PRMT5 knockout and point-mutation models; drug sensitivity assays |
| PNP | Immunodeficiency; PNP deficiency causes T-cell dysfunction | PNP knockout cell lines and patient-derived models |
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout models; adenosine toxicity assays |
| HPRT1 | Lesch-Nyhan syndrome; purine salvage defect | HPRT1 knockout cells; purine metabolite profiling |
Cancer and synthetic lethality
MTAP deletion occurs in a significant fraction of cancers and leads to accumulation of the purine nucleoside metabolite methylthioadenosine (MTA). MTA binds and inhibits PRMT5, creating a dependency on PRMT5 that can be exploited therapeutically. This synthetic lethal scenario is a paradigm for targeting purine nucleoside binding and metabolism in oncology.
Immunodeficiency and purine metabolism disorders
Deficiencies in purine nucleoside metabolizing enzymes, such as adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP), cause severe immunodeficiencies due to toxic accumulation of purine nucleosides. These disorders highlight the importance of precise purine nucleoside binding and turnover for lymphocyte function.
Parasitic infections
Purine nucleoside phosphorylases from parasites are essential for purine salvage and are considered drug targets. Inhibitors designed to block purine nucleoside binding in parasite PNP are being explored as antiparasitic agents.
Neurological and metabolic conditions
Altered purine nucleoside binding and metabolism have been implicated in neurological conditions and metabolic disorders, including gout and Lesch-Nyhan syndrome, through effects on purine salvage and catabolism.
From purine nucleoside binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MTAP alter sensitivity to PRMT5 inhibitors? | MTAP knockout isogenic cell lines |
| Does a point mutation in the PNP active site abolish purine nucleoside binding? | PNP point-mutation knock-in cell lines |
| Can a tagged PNP be used to map purine nucleoside binding sites? | Tagged knock-in of PNP with affinity or fluorescent tag |
| Does overexpression of PRMT5 rescue MTA-induced growth inhibition? | PRMT5 overexpression in MTAP-deleted cells |
| Which genes modulate sensitivity to purine nucleoside analogs? | Genome-wide CRISPR knockout library screening |
| Does restoration of MTAP reverse MTA accumulation and PRMT5 inhibition? | MTAP knock-in or overexpression in MTAP-deleted cells |
How to Study the purine nucleoside binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of protein-ligand complexes | Visualizing purine nucleoside binding in PNP |
| Isothermal titration calorimetry | Binding affinity and stoichiometry | Quantifying purine nucleoside binding and cooperativity |
| Binding isotope effects | Transition-state interactions | Validating transition-state analogue design |
| Enzyme kinetics | Catalytic rate and inhibition constants | Characterizing PNP inhibitors |
| CRISPR knockout screens | Gene essentiality and drug sensitivity | Identifying synthetic lethal partners of MTAP deletion |
| Metabolomics (LC-MS) | Levels of purine nucleosides and nucleotides | Measuring MTA accumulation in MTAP-deleted cells |
| Surface plasmon resonance | Real-time binding kinetics | Screening purine nucleoside analogs |
| Fluorescence polarization | Binding of fluorescent nucleoside probes | High-throughput screening for binders |
Structural biology and binding assays
X-ray crystallography and cryo-EM can capture purine nucleoside binding snapshots, as demonstrated for hexameric PNP. Isothermal titration calorimetry and surface plasmon resonance measure binding affinity and cooperativity. Binding isotope effects provide direct evidence for transition-state interactions.
Kinetic and inhibition studies
Enzyme kinetics with purine nucleoside substrates and inhibitors reveal catalytic parameters and mechanisms. Transition-state analogue design and testing are used to validate binding models. Symmetric nucleoside inhibitors can be tested for potency against PNP.
CRISPR functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to purine nucleoside binding inhibitors or MTA accumulation. Focused screens on purine metabolism genes can reveal synthetic lethal interactions.
Metabolomics and flux analysis
Mass spectrometry-based metabolomics quantifies purine nucleosides such as MTA and adenosine, linking binding function to cellular metabolism. Stable isotope tracing can measure purine salvage flux.
How CRISPR Can Be Used to Study GO:0001883 purine nucleoside binding
Knockout
CRISPR knockout of MTAP in cancer cell lines recapitulates MTA accumulation and PRMT5 dependency, providing a model for synthetic lethality studies. Knockout of PNP or ADA can model purine nucleoside metabolism disorders.
Point Mutation
Point mutations in the active site of PNP can be introduced to dissect the contribution of specific residues to purine nucleoside binding and catalysis. Such models help validate structural predictions and transition-state interactions.
Knock-in
Knock-in of tagged PNP or MTAP allows affinity purification and localization studies of purine nucleoside binding complexes. Knock-in of disease-associated mutations can model altered binding affinity.
Overexpression
Overexpression of PRMT5 or MTAP can rescue or exacerbate phenotypes linked to purine nucleoside binding, such as MTA sensitivity. Overexpression of nucleoside transporters can increase cellular uptake of purine nucleoside analogs.
How EDITGENE Supports purine nucleoside binding Research
Researchers studying purine nucleoside binding-related genes often need to determine whether a candidate gene is causally involved in a disease phenotype or drug response. EDITGENE provides CRISPR-based cell model services that enable precise knockout, point mutation, knock-in, and overexpression of genes such as MTAP, PNP, and PRMT5, accelerating functional validation and therapeutic target discovery.
Contact EDITGENE today to design your custom CRISPR model for purine nucleoside binding research.
Frequently Asked Questions About purine nucleoside binding
What is GO:0001883 purine nucleoside binding?
GO:0001883 is a Gene Ontology molecular function term describing the binding to a purine nucleoside, a compound consisting of a purine base linked to ribose or deoxyribose.
What genes are involved in purine nucleoside binding?
Key genes include PNP, MTAP, PRMT5, ADA, ADK, and nucleoside transporters such as SLC29A1 and SLC28A2.
How is purine nucleoside binding studied?
It is studied using X-ray crystallography, binding isotope effects, enzyme kinetics, and CRISPR-based functional genomics.
Why is MTAP deletion important for purine nucleoside binding?
MTAP deletion causes accumulation of the purine nucleoside MTA, which binds and inhibits PRMT5, creating a synthetic lethal dependency in cancer.
What diseases are linked to purine nucleoside binding defects?
Defects are linked to immunodeficiencies, cancer, parasitic infections, and metabolic disorders such as Lesch-Nyhan syndrome.
What is the role of purine nucleoside phosphorylase in this function?
PNP binds purine nucleosides and catalyzes their phosphorolysis, serving as the prototype enzyme for GO:0001883.
Can CRISPR be used to study purine nucleoside binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in purine nucleoside metabolism.
What are transition-state analogues of purine nucleoside phosphorylase?
They are designed molecules that mimic the transition state of purine nucleoside binding and catalysis, providing tight-binding inhibitors.
How does oligomeric assembly affect purine nucleoside binding?
Oligomeric PNP can exhibit one-third-of-the-sites binding and cooperativity, which modulates binding affinity and catalysis.
What experimental models are used for MTAP-deleted cancers?
Isogenic MTAP knockout and knockout-rescue cell lines, along with PRMT5 inhibitor sensitivity assays, are commonly used.
Conclusion
GO:0001883 purine nucleoside binding is a fundamental molecular function that underpins purine salvage, nucleoside metabolism, and cellular responses to metabolites such as MTA. Its best-characterized exemplar, purine nucleoside phosphorylase, has provided deep mechanistic insights through structural biology, kinetics, and transition-state analogue design. In disease, MTAP deletion and MTA accumulation create a synthetic lethal dependency on PRMT5, highlighting the therapeutic relevance of this function. CRISPR-based cell models are indispensable for dissecting the causal roles of purine nucleoside binding proteins in cancer, immunodeficiency, and metabolic disorders. EDITGENE offers comprehensive knockout, point-mutation, knock-in, overexpression, and library screening services to accelerate research on GO:0001883 and its associated genes.
References
- 1. Rodon J et al.. 2026. MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.. Cancer Res 86(7):1558-1569 PMID: 41512197
- 2. Kryukov GV et al.. 2016. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.. Science 351(6278):1214-8 PMID: 26912360
- 3. Lewandowicz A. 2004. [Tight binding transition state analogues of purine nucleoside phosphorylase--meaning, design and properties].. Postepy Biochem 50(3):218-27 PMID: 15822751
- 4. Štefanić Z et al.. 2018. Crystallographic snapshots of ligand binding to hexameric purine nucleoside phosphorylase and kinetic studies give insight into the mechanism of catalysis.. Sci Rep 8(1):15427 PMID: 30337572
- 5. Bzowska A et al.. 2000. Purine nucleoside phosphorylases: properties, functions, and clinical aspects.. Pharmacol Ther 88(3):349-425 PMID: 11337031
- 6. Wielgus-Kutrowska B et al.. 2012. Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state.. Bioorg Med Chem 20(22):6758-69 PMID: 23040896
- 7. Pant P et al.. 2021. Symmetric Nucleosides as Potent Purine Nucleoside Phosphorylase Inhibitors.. J Phys Chem B 125(11):2856-2862 PMID: 33715357
- 8. Murkin AS et al.. 2008. Transition-state interactions revealed in purine nucleoside phosphorylase by binding isotope effects.. J Am Chem Soc 130(7):2166-7 PMID: 18229929
